Drugs / Aipaluoli-tovorilimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07622836 | Jun 2026 → Jan 2030 expected | lymph node cancer, triple-negative breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aipaluoli-tovorilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622836 ↗ |